Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. Pulmatrix’s lead clinical asset (PUR0200) is a long acting bronchodilator formulated in iSPERSE which is currently in Phase II clinical trials in COPD.
In addition, Pulmatrix is working in multiple external partnerships committed to developing breakthrough technologies and formulations for the treatment of respiratory diseases based on the iSPERSE platform. In our own novel iSPERSE pipeline, Pulmatrix has the ability to develop single and combination therapies that will provide advances in current standard of care and novel drug formulations that will improve patient outcomes, compliance, and convenience. Pulmatrix is particularly focused on improving the lives of patients with chronic respiratory diseases including asthma, COPD, and CF.